Table 3.

Frequency and characteristics of disease progression after combined HIPEC+ACT administration

Characteristics of disease progression	TNM			Total n = 19 (100%)
	T4a-bN0, n = 5 (26.3%)	T4a-bN1, n = 7 (36.8%)	T4a-bN2–3, n = 7 (36.8%)
Peritoneal cancer dissemination	0	0	1 (14.3)	> 0.99
Progression (without peritoneal dissemination)	0	3 (42.9)	3 (42.9)	0.278
Distant metastasis of a different localization
Liver metastasis	0	1 (14.3)	0	> 0.99
Metastasis in non-regional lymph nodes	0	2 (28.6)	1 (14.3)	0.747
Bone metastasis	0	1(14.3)	3 (42.9)	0.381
Death from cancer progression	0	0	2 (28.6)	0.304